In a nutshell This paper investigates which approach provides longer recurrence free survival time after breast conserving surgery – pre- or post-operative chemotherapy. Some background Breast conserving surgery (lumpectomy) or BCS is surgery to remove the cancer and a section of healthy tissue around it. Women who choose this...
Read MoreType(s) of breast cancer-Ductal carcinoma-Invasive ductal carcinoma Posts on Medivizor
Repeat conservative breast surgery for patients with breast cancer recurring in the same breast
In a nutshell The aim of this study was to establish the criteria for selecting the best candidates to receive a second breast–conserving surgery (BCS) after ipsilateral breast tumor recurrence (IBTR- reappearance of a breast tumor on the same side). Some background Some patients with primary breast cancer who receive BCS and...
Read MoreBosutinib: a new drug that increases progression free survival in patients with locally advanced or metastatic breast cancer
In a nutshell This paper presents the results of a clinical study which looked at the use of a new drug called Bosutinib (Bosulif) for the treatment of breast cancers diagnosed as being stage III or IV. In patients previously treated with chemotherapy, Bosutinib showed promising efficacy in delaying cancer progression. Some background Locally...
Read MoreEribulin (Halaven) versus other treatment options in women with stage IV breast cancer
In a nutshell This study compared the efficacy of Eribulin (Halaven) versus other treatments in women with previously treated stage IV breast cancer. Eribulin extended overall survival more than the other treatment options. Some background Late stage breast cancer offers limited treatment options. At this point in the disease,...
Read MoreBenefits of post-operative chemotherapy according to hormone receptor status
In a nutshell This study compared the benefits of chemotherapy according to hormone receptor status. The main findings were: In cancers without hormone receptors, the benefits of adding chemotherapy were significant; In cancers with hormone receptors, chemotherapy only offered modest improvement. Some background Some...
Read MoreEvaluating the addition of Capecitabine to postoperative standard chemotherapy
In a nutshell This article presents summarized data from two clinical trials. The trials evaluated the addition of Capecitabine to standard postoperative chemotherapy for patients with high risk early breast cancer. Some background Capecitabine is a chemotherapy drug that is taken orally and slows the growth of tumors. It can be...
Read MorePreserving Fertility during Cancer Treatment
In a nutshell This paper reviews available options for having children after cancer treatment. The main conclusion is that sperm, egg and embryo preservation techniques can help young women have children after breast cancer treatment. Alternative options, such as ovarian tissue preservation, are also being developed. Some background...
Read MoreStandard Chemotherapy versus Capecitabine (Xeloda) in Older Women with Early-Stage Breast Cancer
In a nutshell This trial compared standard chemotherapy regimens and Capecitabine (Xeloda) in women over 65 years old. The main outcome was that standard chemotherapy worked better in this age group. Some background Capecitabine is generally used in breast cancer resistant to other chemotherapy. It is also the first approved treatment that can be...
Read MoreWhat is the preferred duration of chemotherapy? – A review of clinical trials
The aim of this paper was to identify if a longer course of chemotherapy was better than a short course. The authors look at how long patients survived with metastatic breast cancer or with no further cancer progression. Breast cancer is called metastatic when it has spread from the breast to other parts of the body such as the lymph nodes, lungs,...
Read More
